David Halverson has been appointed president of Protea Biosciences. He has more than 20 years of management experience in the pharmaceutical services industry, including serving as a director of sales for PPD Discovery and the Quintiles Preclinical Groups. 
 
Mr. Halverson previously served as Protea’s vice president and chief business officer. Prior to joining the company, he was served in various capacities at Huntingdon Life Sciences, including head of European and U.S. sales.  
 
“We are pleased to announce the selection of David Halverson as president of Protea Biosciences,” said Steve Turner, Protea’s chairman and chief executive officer. “David has led the successful development of our proprietary molecular information services business. He is building a strong and growing customer base, which now includes major pharmaceutical and biotechnology companies; he is ideally suited to manage our business operations, as we position Protea to meet and lead the global demand for better molecular information, for improved pharmaceutical development.”